Exact Sciences Corporation

    Exact Sciences Corporation

    NNASDAQ:EXAS
    104.91
    USD
    0.00
    (0.00%)
    2013 Y
    2014 Y
    2015 Y
    2016 Y
    2017 Y
    2018 Y
    2019 Y
    2020 Y
    2021 Y
    2022 Y
    2023 Y
    2024 Y
    2025 Y
    TTM
    Revenue per Share
    0.06
    0.02
    0.43
    0.97
    2.3
    3.72
    6.68
    9.87
    10.31
    11.82
    13.88
    14.98
    17.21
    17.24
    Basic EPS, GAAP
    -0.69
    -1.25
    -1.71
    -1.63
    -0.99
    -1.43
    -1.62
    -5.45
    -3.48
    -3.54
    -1.13
    -5.59
    -1.1
    -1.1
    Free Cash Flow per Basic Share
    -0.73
    -1.16
    -1.69
    -1.42
    -1.22
    -1.8
    -2.17
    0.47
    -1.39
    -2.48
    0.18
    0.4
    1.89
    2.22
    Dividend per Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Book Value per Share
    -4.74
    -5.23
    -6.27
    -7.28
    -7.43
    -8.47
    -8.52
    -13.53
    -15.41
    -18.5
    -19.25
    -24.41
    -24.93
    -24.98
    Tangible Book Value per Share
    2
    3.6
    3.55
    3.26
    4.29
    5.19
    -0.45
    1
    -6.08
    -7.14
    -6.17
    -5.29
    -4.7
    -4.71
    Basic Weighted Avg Shares
    67
    80
    92
    102
    116
    122
    131
    151
    171
    176
    180
    184
    189
    188
    Sales/Revenue/Turnover
    4
    2
    39
    99
    266
    454
    876
    1,491
    1,767
    2,084
    2,500
    2,759
    3,247
    3,247
    Operating Margin (%)
    -1,127.22
    -5,588.38
    -403.47
    -170.08
    -44.48
    -35.09
    -26.68
    -37.42
    -47.28
    -27.71
    -8.58
    -6.5
    -6.13
    -6.13
    Depreciation Expense
    1
    4
    8
    12
    16
    23
    50
    163
    180
    198
    207
    215
    222
    222
    Net Income, GAAP
    -47
    -100
    -158
    -167
    -114
    -175
    -213
    -824
    -596
    -624
    -204
    -1,029
    -208
    -208
    Effective Tax Rate (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Profit Margin (%)
    -1,122.44
    -5,564.4
    -400.14
    -168.26
    -43.01
    -38.54
    -24.32
    -55.22
    -33.71
    -29.91
    -8.17
    -37.29
    -6.4
    -6.4
    Working Capital
    128
    274
    299
    303
    419
    1,092
    317
    1,565
    909
    570
    680
    839
    915
    915
    LT Debt
    3
    3
    6
    5
    4
    689
    946
    2,005
    2,362
    2,419
    2,475
    2,478
    2,489
    2,489
    Total Equity
    135
    289
    327
    335
    520
    681
    2,288
    2,236
    3,388
    3,043
    3,145
    2,402
    2,401
    2,401
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -

    Capital Structure

    USD

    •

    in mil. unless spec.
    Jun'25
    Sep'25
    Dec'25
    ST Debt
    31
    32
    34
    LT Borrowings
    2,324
    2,326
    2,327
    LT Finance Leases
    166
    164
    162
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    189
    189
    191
    Market Capitalization
    9,908
    10,262
    19,126

    Working Capital

    USD

    •

    in mil. unless spec.
    Jun'25
    Sep'25
    Dec'25
    Total Current Assets
    1,508
    1,591
    1,556
    Cash, Cash Equivalents & STI
    858
    1,003
    965
    Accounts Receivable, Net
    - -
    - -
    - -
    Inventories
    171
    165
    166
    Total Current Liabilities
    522
    584
    641
    Payables & Accruals
    474
    538
    316
    ST Debt
    31
    32
    34
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    34.34%
    4.21%
    -0.05%
    Free Cash Flow
    0.58%
    11.1%
    378.6%
    Net Income, GAAP
    56.96%
    46.78%
    -79.79%
    Sales/Revenue/Turnover
    63.8%
    16.89%
    17.69%
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    602
    622
    628
    647
    2,500
    2024
    638
    699
    709
    713
    2,759
    2025
    707
    811
    851
    878
    3,247

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    -0.42
    -0.45
    - -
    - -
    -1.13
    2024
    -0.6
    -0.09
    -0.21
    -4.67
    -5.59
    2025
    -0.54
    -0.01
    -0.1
    - -
    -1.1

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -

    Company Description

    Company Profile APIChatGPT
    Address
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • marketbeat.com

      Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street

    • seekingalpha.com

      Abbott Laboratories Q2 Earnings Preview: A Contrarian Buy Opportunity Worth Considering

    • proactiveinvestors.com

      Abbott Labs shares fall as earnings beat offset by Exact Sciences acquisition drag

    • defenseworld.net

      96,685 Shares in Exact Sciences Corporation $EXAS Purchased by Capricorn Fund Managers Ltd

    • defenseworld.net

      Exact Sciences Corporation $EXAS Shares Sold by Exchange Traded Concepts LLC

    • defenseworld.net

      FNY Investment Advisers LLC Buys Shares of 28,500 Exact Sciences Corporation $EXAS

    • defenseworld.net

      Banque Pictet & Cie SA Lowers Position in Exact Sciences Corporation $EXAS

    • businesswire.com

      Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026

    • defenseworld.net

      Bridgefront Capital LLC Buys Shares of 11,994 Exact Sciences Corporation $EXAS

    • defenseworld.net

      ArrowMark Colorado Holdings LLC Purchases 113,603 Shares of Exact Sciences Corporation $EXAS

    • defenseworld.net

      Exact Sciences Corporation $EXAS Shares Bought by Dimensional Fund Advisors LP

    • zacks.com

      Exact Sciences (EXAS) is a Top-Ranked Momentum Stock: Should You Buy?

    • zacks.com

      CSLLY or EXAS: Which Is the Better Value Stock Right Now?

    • businesswire.com

      Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year

    • businesswire.com

      Marking National Colorectal Cancer Awareness Month, Privia Health Program Achieves 84% Colorectal Cancer Screening Rate Through Industry Collaboration

    • defenseworld.net

      DNB Asset Management AS Raises Position in Exact Sciences Corporation $EXAS

    • businesswire.com

      Exact Sciences Stockholders Approve Acquisition by Abbott

    • zacks.com

      Here's Why Exact Sciences (EXAS) is a Strong Momentum Stock

    • zacks.com

      Exact Sciences Q4 Earnings Match Estimates, Revenues Beat, Stock Up

    • defenseworld.net

      Aberdeen Group plc Increases Stock Position in Exact Sciences Corporation $EXAS